Tianchen Biomedical

Tianchen Biomedical is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on developing innovative biologics for ophthalmology and allergic diseases. The company utilizes its proprietary antibody discovery and high-concentration formulation platforms to create a pipeline of monoclonal and bispecific antibodies. Its lead candidate, LP-003, is a next-generation anti-IgE antibody currently in Phase 2 trials for allergic rhinitis and chronic spontaneous urticaria, designed for improved efficacy and less frequent dosing. Tianchen's ophthalmic pipeline includes LP-001 for neovascular age-related macular degeneration and LP-005, a bispecific antibody targeting both VEGF and ANG2. The leadership team consists of industry veterans with extensive experience in global biologics R&D and manufacturing.